AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32911474 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 1284
Study 33063321 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-compassion resources
Number of subjects: 248
Study 33063321 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 248
Study 33112518 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical approach
Number of subjects: 0
Study 33112518 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive technique
Number of subjects: 0
Study 35121700 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (900-2400 mg/day)
Number of subjects: 0
Study 35121700 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate (about 20 mg/kg/day)
Number of subjects: 0
Study 33663021 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) exercises, 28 min sessions, three times a week for 8 weeks
Number of subjects: 49
Study 33663021 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PMR intervention)
Number of subjects: 49
Study 33814236 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a)
Number of subjects: 1030836
Study 33814236 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-cholesterol
Number of subjects: 1030836
Study 33814236 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-cholesterol
Number of subjects: 1030836
Study 33814236 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 1030836
Study 33814236 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoA1
Number of subjects: 1030836
Study 33814236 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoB
Number of subjects: 1030836
Study 32130025 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion for 7 hours at night
Number of subjects: 11
Study 32130025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusion for 7 hours at night
Number of subjects: 11
Study 32130025 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 11
Study 32130025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 11
Study 35861588 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab (300 mg single dose; 450 mg every 4 weeks; or 1,200 mg every 4 weeks, three doses)
Number of subjects: 128
Study 35861588 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab
Number of subjects: 128
Study 35861588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 36282078 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (0.1 mg.kg‐1 daily)
Number of subjects: 60
Study 36282078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (0.25 mg.kg‐1 two times a day)
Number of subjects: 60
Study 36282078 — intervention group
Group type: COMPARATOR
Intervention: Control group (Conventional thalassemia and PHT management)
Number of subjects: 60
Study 35300246 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodal therapy followed by gemcitabine plus cetuximab maintenance (Arm B)
Number of subjects: 68
Study 35300246 — intervention group
Group type: COMPARATOR
Intervention: Trimodal therapy followed by gemcitabine maintenance (Arm A)
Number of subjects: 68
Study 35300246 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodal therapy consisting of IMRT, gemcitabine and cetuximab
Number of subjects: 68
Study 32208443 — intervention group
Group type: COMPARATOR
Intervention: Chest compression depth target of 'approximately 4 cm' (Group A)
Number of subjects: 40
Study 32208443 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compression depth target of 'at least one-third the anterior-posterior diameter of the chest' (Group B)
Number of subjects: 40
Study 32208443 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb technique (TT) with 'at least one-third the anterior-posterior diameter of the chest' (Group B)
Number of subjects: 40
Study 32208443 — intervention group
Group type: COMPARATOR
Intervention: Two-thumb technique (TT) with 'approximately 4 cm' (Group A)
Number of subjects: 40
Study 35776901 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional schedule radiation therapy
Number of subjects: 267
Study 35776901 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated radiation therapy
Number of subjects: 267
Study 35776901 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC subdomain data
Number of subjects: 267
Study 35776901 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cross-sectional data
Number of subjects: 267
Study 34515448 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-fragmented autologous adipose tissue injection
Number of subjects: 114
Study 34515448 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 114
Study 33241972 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC+ (carrying +15% of body weight in a vest)
Number of subjects: 32
Study 33241972 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC
Number of subjects: 32
Study 33241972 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 32
Study 33241972 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC+
Number of subjects: 32
Study 33941795 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS combined with SVM
Number of subjects: 82
Study 33941795 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM with the top 50 feature wavenumbers
Number of subjects: 82
Study 32648662 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium 25 mg for 3 months
Number of subjects: 76
Study 32648662 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 76
Study 32648662 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium 25 mg
Number of subjects: 76
Study 32648662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 34613330 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal drainage tube (TDT)
Number of subjects: 560
Study 34613330 — intervention group
Group type: COMPARATOR
Intervention: Non-transanal drainage tube (non-TDT)
Number of subjects: 560
Study 35158293 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous maxillary expansion and mandibular advancement
Number of subjects: 94
Study 35158293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 94
Study 32458310 — intervention group
Group type: EXPERIMENTAL
Intervention: HCAG
Number of subjects: 94
Study 32458310 — intervention group
Group type: COMPARATOR
Intervention: CAG
Number of subjects: 94
Study 34217550 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM-based rational use of drugs training
Number of subjects: 132
Study 34217550 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 132
Study 34846525 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with RT
Number of subjects: 589
Study 34846525 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine and oxaliplatin with RT
Number of subjects: 589
Study 35254628 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 0
Study 35254628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33272334 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed cartilage graft
Number of subjects: 46
Study 33272334 — intervention group
Group type: COMPARATOR
Intervention: Intact cartilage graft (control)
Number of subjects: 46
Study 35753564 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (cathodal)
Number of subjects: 110
Study 35753564 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 110
Study 32586736 — intervention group
Group type: EXPERIMENTAL
Intervention: tezacaftor/ivacaftor
Number of subjects: 97
Study 32586736 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97
Study 36153030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) programme comprising 16 twice‐weekly group sessions tailored to the Georgian setting.
Number of subjects: 60
Study 36153030 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 34028828 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment and Hall Technique (ART/HT)
Number of subjects: 65
Study 34028828 — intervention group
Group type: COMPARATOR
Intervention: Dental general anaesthesia (DGA)
Number of subjects: 65
Study 33278014 — intervention group
Group type: EXPERIMENTAL
Intervention: Kindness to Others
Number of subjects: 97
Study 33278014 — intervention group
Group type: COMPARATOR
Intervention: Kindness to Self
Number of subjects: 97
Study 33278014 — intervention group
Group type: COMPARATOR
Intervention: Daily Report
Number of subjects: 97
Study 32016654 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute GA
Number of subjects: 240
Study 32016654 — intervention group
Group type: COMPARATOR
Intervention: GA remission
Number of subjects: 240
Study 32016654 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic HUA
Number of subjects: 240
Study 32016654 — intervention group
Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 240
Study 32016654 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride and LDL-C
Number of subjects: 240
Study 33559944 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) for 6 weeks, 20-25 minutes, 3 times a week (18 sessions)
Number of subjects: 28
Study 33559944 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study 33559944 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 28
Study 32271290 — intervention group
Group type: EXPERIMENTAL
Intervention: KE group (knees extended)
Number of subjects: 32
Study 32271290 — intervention group
Group type: EXPERIMENTAL
Intervention: KF group (knees flexed)
Number of subjects: 32
Study 32271290 — intervention group
Group type: COMPARATOR
Intervention: CON group (control)
Number of subjects: 32
Study 36173064 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-dose intravenous ketamine
Number of subjects: 75
Study 33759439 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise plus interferential currents (N=25)
Number of subjects: 49
Study 33759439 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise only (N=24)
Number of subjects: 49
Study 36470641 — intervention group
Group type: EXPERIMENTAL
Intervention: M-ROCC (Mindful Recovery OUD Care Continuum)
Number of subjects: 18
Study 34145939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycaemic control
Number of subjects: 144
Study 34145939 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycaemic control
Number of subjects: 144
Study 35664433 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (sepsis patients)
Number of subjects: 60
Study 35664433 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (sepsis patients with diabetes mellitus)
Number of subjects: 60
Study 35664433 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60
Study 34192942 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical fixation
Number of subjects: 0
Study 34192942 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilization
Number of subjects: 0
Study 33004704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine (1 μg/kg dexmedetomidine and 0.5 mg/kg ketamine)
Number of subjects: 60
Study 33004704 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-ketamine (2 μg/kg fentanyl and 0.5 mg/kg ketamine)
Number of subjects: 60
Study 33004704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 35737566 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat area (VFA) of ≥100 cm2 in subjects without extensive gastric mucosal atrophy (GA)
Number of subjects: 64
Study 35737566 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat area (VFA) in subjects with extensive gastric mucosal atrophy (GA)
Number of subjects: 64
Study 34233722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cybernic treatment with HAL (40-min walking program performed nine times)
Number of subjects: 30
Study 34233722 — intervention group
Group type: COMPARATOR
Intervention: Hoist only treatment
Number of subjects: 30
Study 34233722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cybernic treatment with HAL
Number of subjects: 30
Study 35027057 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid test (GeneXpert GBS system, Cepheid)
Number of subjects: 1628
Study 35027057 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1628
Study 35027057 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid test
Number of subjects: 1628
Study 32469811 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive movie clip combined with electrical shocks (acute stress stimulation)
Number of subjects: 35
Study 32469811 — intervention group
Group type: COMPARATOR
Intervention: Neutral movie clip (control stimulation)
Number of subjects: 35
Study 36332179 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab (15 mg/kg intravenously once every 3 weeks)
Number of subjects: 536
Study 36332179 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab (6 mg/kg intravenously once every 3 weeks after a loading dose of 8 mg/kg)
Number of subjects: 536
Study 36332179 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab in CD16A-158FF patients
Number of subjects: 536
Study 36332179 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab in CD16A-158VV patients
Number of subjects: 536
Study 34393085 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 246
Study 34393085 — intervention group
Group type: COMPARATOR
Intervention: ASA
Number of subjects: 246
Study 32932233 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-training group (exercises: countermovement jump and BP throw; sets per exercise: 4-6; repetitions per set: 5-6; load: 40% 1RM)
Number of subjects: 30
Study 32932233 — intervention group
Group type: COMPARATOR
Intervention: Strength-training group (exercises: SQ and BP; sets per exercise: 4-6; repetitions per set: 2-8; load: 70%-90% 1RM)
Number of subjects: 30
Study 35627588 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% povidone-iodine (PI) preprocedural rinse
Number of subjects: 10
Study 35627588 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil (EO) preprocedural rinse
Number of subjects: 10
Study 35627588 — intervention group
Group type: COMPARATOR
Intervention: Water as preprocedural rinse
Number of subjects: 10
Study 34187391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle weight intervention (1.1 kg on each ankle) worn during daily activities for 6 months
Number of subjects: 160
Study 34187391 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control group
Number of subjects: 160
Study 34187391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle weight intervention
Number of subjects: 160
Study 32624468 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management app (€ Be‐with‐You')
Number of subjects: 476
Study 32624468 — intervention group
Group type: COMPARATOR
Intervention: General health app (€ Sham' app)
Number of subjects: 476
Study 34784787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral stimulation and supplemental nursing system
Number of subjects: 70
Study 34784787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 34003825 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about COVID-19
Number of subjects: 634
Study 34003825 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude towards COVID-19
Number of subjects: 634
Study 34003825 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of clinical symptoms of COVID-19
Number of subjects: 634
Study 34003825 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about being infected with COVID-19
Number of subjects: 634
Study 34003825 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical distancing practices
Number of subjects: 634
Study 34003825 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge associated with age
Number of subjects: 634
Study 34003825 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge associated with urban living
Number of subjects: 634
Study 34003825 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude associated with information about COVID-19
Number of subjects: 634
Study 32138607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster training (16 sets of 2 repetitions with 1 min rest between sets and 5 min between exercises)
Number of subjects: 0
Study 32138607 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (4 sets of 8 repetitions with 5 min rest between sets and exercises)
Number of subjects: 0
Study 34400254 — intervention group
Group type: EXPERIMENTAL
Intervention: N-of-1 trial treatment regimen
Number of subjects: 0
Study 616763896 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer support for 9 months
Number of subjects: 74
Study 616763896 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 74
Study 35063452 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 6 months
Number of subjects: 100
Study 35063452 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nasal dilator strips) for 6 months
Number of subjects: 100
Study 35131817 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 160
Study 35131817 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 160
Study 32027349 — intervention group
Group type: EXPERIMENTAL
Intervention: On-time visit adherence (avg days = 28-35 days)
Number of subjects: 1178
Study 32027349 — intervention group
Group type: EXPERIMENTAL
Intervention: Late visit adherence (avg days = 36-60 days)
Number of subjects: 1178
Study 32027349 — intervention group
Group type: EXPERIMENTAL
Intervention: Very late visit adherence (avg days > 60 days)
Number of subjects: 1178
Study 34494375 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/wk of exercise
Number of subjects: 298
Study 34494375 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 min/wk of exercise
Number of subjects: 298
Study 34494375 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 min/wk of exercise
Number of subjects: 298
Study 34494375 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight maintenance intervention
Number of subjects: 298
Study 34494375 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 298
Study 35976398 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric early tumor shrinkage (ETS) ≥ 45%
Number of subjects: 253
Study 35976398 — intervention group
Group type: EXPERIMENTAL
Intervention: Diametric early tumor shrinkage (ETS) ≥ 20%
Number of subjects: 253
Study 34104306 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum depression screening using Edinburg Postnatal Depression Scale
Number of subjects: 380
Study 32227309 — intervention group
Group type: EXPERIMENTAL
Intervention: S. salivarius K12 tablet
Number of subjects: 28
Study 32227309 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 28
Study 36428171 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy plus abiraterone with or without apalutamide
Number of subjects: 124
Study 36428171 — intervention group
Group type: COMPARATOR
Intervention: Control group (RP without neoadjuvant therapy)
Number of subjects: 124
Study 33970403 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 0
Study 33970403 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 32197766 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth follow-up visits
Number of subjects: 66
Study 32197766 — intervention group
Group type: COMPARATOR
Intervention: Control (office follow-up)
Number of subjects: 66
Study 616490674 — intervention group
Group type: EXPERIMENTAL
Intervention: GP prescriber
Number of subjects: 928
Study 616490674 — intervention group
Group type: COMPARATOR
Intervention: SCC prescriber
Number of subjects: 928
Study 616490674 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs willing to prescribe
Number of subjects: 928
Study 35622367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (10-lb boxes of fruits and vegetables, $10 grocery gift cards, additional $10 gift card for task completion, $25 food preparation tool)
Number of subjects: 68
Study 35622367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 35622367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group compared to control group
Number of subjects: 68
Study 35998937 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG block with 20 mL of 0.5% ropivacaine
Number of subjects: 68
Study 35998937 — intervention group
Group type: COMPARATOR
Intervention: Sham injection with 5 mL of 0.9% normal saline
Number of subjects: 68
Study 36373628 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application providing a structured resilience curriculum for 3 months
Number of subjects: 20
Study 36373628 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 20
Study 33676417 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder pain on arm activity (VAS)
Number of subjects: 193
Study 33676417 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-Murley score (CS)
Number of subjects: 193
Study 33676417 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Shoulder Test (SST)
Number of subjects: 193
Study 33676417 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder pain at rest (VAS)
Number of subjects: 193
Study 33355261 — intervention group
Group type: EXPERIMENTAL
Intervention: QPM seed with consumption targeting intervention
Number of subjects: 610
Study 33355261 — intervention group
Group type: COMPARATOR
Intervention: QPM seed only
Number of subjects: 610
Study 36174006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tritipyrum line (Ka/b)(Cr/b)‐5
Number of subjects: 17
Study 36174006 — intervention group
Group type: EXPERIMENTAL
Intervention: Triticale lines (M45, 4115, 4108)
Number of subjects: 17